Kala Bio
Biotechnology Research • 
Arlington, Massachusetts, United States • 101-200 Employees
Company overview
| Headquarters | 1167 Massachusetts Ave, Arlington, Massachusetts 02476, US |
| Phone number | +17819965252 |
| Website | |
| NAICS | 541714 |
| SIC | 283 |
| Founded | 2009 |
| Employees | 101-200 |
| Socials |
Key Contact at Kala Bio
Kala Bio Email Formats
Kala Bio uses 3 email formats. The most common is {first name}.{last name} (e.g., john.doe@kalarx.com), used 54.2% of the time.
| Format | Example | Percentage |
|---|---|---|
{first name}.{last name} | john.doe@kalarx.com | 54.2% |
{first initial}.{last name} | j.doe@kalarx.com | 41.7% |
{first name}{last name} | johndoe@kalarx.com | 4.2% |
About Kala Bio
Weaving along Hawaii's Na Pali Coast is the famous, breathtaking Kalalau trail. This trail is not only notable for its strenuous path and terrain that is difficult to traverse, but also known for its unsurpassed beauty. Kalalau was early inspiration for us, today representing our innovative spirit and deep commitment to advancing the treatment of eye diseases. KALA BIO is a clinical-stage biopharmaceutical company dedicated to the research and development of innovative therapies for rare and severe diseases of the eye. KALA BIO’s biologics-based investigational therapies utilize KALA BIO’s proprietary mesenchymal stem cell secretome (MSC-S) platform. KALA BIO’s lead product candidate, KPI-012, is a human MSC-S, which contains numerous human-derived biofactors, such as growth factors, protease inhibitors, matrix proteins and neurotrophic factors that can potentially correct the impaired corneal healing that is an underlying etiology of multiple severe ocular diseases. KPI-012 is currently in clinical development for the treatment of persistent corneal epithelial defect (PCED), a rare disease of impaired corneal healing, for which it has received Orphan Drug and Fast Track designations from the U.S. Food and Drug Administration. KALA BIO is also targeting the potential development of KPI-012 for the treatment of Limbal Stem Cell Deficiency and other rare corneal diseases that threaten vision and has initiated preclinical studies to evaluate the potential utility of its MSC-S platform for retinal degenerative diseases, such as Retinitis Pigmentosa and Stargardt Disease. For more information on KALA BIO, please visit www.kalarx.com.
Kala Bio revenue & valuation
| Annual revenue | $3,892,000 |
| Revenue per employee | $38,000 |
| Estimated valuation?This valuation is estimated based on industry average for the Biotechnology Research industry and current estimated revenues | $12,500,000 |
| Total funding | No funding |
Employees by Management Level
Total employees: 101-200
Seniority
Employees
Employees by Department
Kala Bio has 32 employees across 10 departments.
Departments
Number of employees
Funding Data
Kala Bio has never raised funding before.
Kala Bio Tech Stack
Discover the technologies and tools that power Kala Bio's digital infrastructure, from frameworks to analytics platforms.
CDN
PaaS
JavaScript libraries
Webmail
CDN
UI frameworks
Miscellaneous
Font scripts
United Kingdom
India
Australia
South Africa
FinlandFrequently asked questions
4.8
40,000 users
